RxDoctor Payments Data

Timothy Allen, MD

Neurology · Fort Collins, CONPI 1164425898

Payments from drug & device makers

$30,507in general payments, 2019–2025

Across 1,343 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • Biogen$3K
  • EMD Serono, Inc.$3K
  • AbbVie$2K
  • AstraZeneca$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$1961%
  • Food & beverage$27,22089%
  • Education$2071%
  • Gifts$2,7339%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis162$5,320
Biogen166$3,420
EMD Serono, Inc.117$3,400
AbbVie(2 entities)134$2,253
AstraZeneca43$1,391
Neurocrine Biosciences, Inc.71$1,311
Amgen(2 entities)42$1,283
Bristol Myers Squibb55$954
Lilly USA, LLC40$923
Sanofi41$911
TG Therapeutics, Inc.31$860
Sunovion Pharmaceuticals Inc.56$842
Lundbeck LLC32$749
UCB, Inc.37$655
Biohaven Pharmaceuticals, Inc.20$521
Pfizer32$489
Teva Pharmaceuticals USA, Inc.35$488
Mallinckrodt Hospital Products Inc.32$447
Argenx US, Inc.14$348
SK Life Science, Inc.14$327
Vanda Pharmaceuticals Inc.9$244
Biohaven Pharmaceutical Holding Company Ltd.16$233
Johnson & Johnson8$227
E.r. Squibb & Sons, L.L.C.7$224
Kyowa Kirin, Inc.10$205
Otsuka America Pharmaceutical, Inc.5$202
Supernus Pharmaceuticals, Inc.11$199
ANI Pharmaceuticals, Inc.11$174
Boston Scientific4$156
Catalyst Pharmaceuticals, Inc.8$149
Grifols USA, LLC5$148
Genentech USA, Inc.7$141
Amneal Pharmaceuticals LLC7$139
Acadia Pharmaceuticals Inc6$122
Mallinckrodt Enterprises LLC5$86
Sumitomo Pharma America, Inc.4$75
Eisai Inc.4$74
Revance Therapeutics, Inc.1$74
Merz Pharmaceuticals, LLC3$65
Acorda Therapeutics, Inc3$62
MDD US Operations, LLC3$60
Alfasigma USA, Inc.3$58
Bausch Health US, LLC2$50
Livanova USA, Inc.1$48
Merz North America, Inc.2$42
Scilex Pharmaceuticals Inc.2$37
Travere Therapeutics, Inc.7$37
Neurelis, Inc.2$34
Life Molecular Imaging Ltd1$31
Jazz Pharmaceuticals Inc.2$30
Octapharma USA, Inc.1$27
Medtronic1$25
CSL Behring1$23
Abbott1$21
GRT US Holding, Inc.1$20
Adamas Pharmaceuticals, Inc.1$18
Cycle Pharmaceuticals Inc1$16
Inspire Medical Systems, Inc.1$15
Tanabe Pharma America, Inc.1$13
Collegium Pharmaceutical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,507 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$145,414
Medicare patients
421
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa31$45,533
AptiomEslicarbazepine Acetate19$29,319
NuedextaDextromethorphan Hbr/Quinidine15$25,039
Nurtec OdtRimegepant Sulfate20$23,539
NeurontinGabapentin13$19,679
BotoxOnabotulinumtoxina15$17,921
Aimovig AutoinjectorErenumab-Aooe25$17,298
Emgality PenGalcanezumab-Gnlm22$14,296
Gabapentin195$4,243
Carbamazepine ErCarbamazepine13$3,842
Memantine Hcl147$3,463
Divalproex Sodium ErDivalproex Sodium28$2,214
Rasagiline Mesylate11$1,975
Topiramate154$1,871
Carbidopa-Levodopa ErCarbidopa/Levodopa31$1,846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$139$45,53331 claims
Sunovion Pharmaceuticals Inc.Aptiom$842$29,31919 claims
PfizerNurtec Odt$489$23,53920 claims
AbbVieBotox$2,253$17,92115 claims
Lilly USA, LLCOlanzapine$923$22228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →